Fourth Quarter and Full Year 2023 Results Call

Corporate Update & Financial Results February 26, 2024





Forward-looking statements

BioCryst's presentation contains forward-looking statements, including statements regarding future results, unaudited and forward-looking financial information and company performance or achievements. These statements are subject to known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements expressed or implied in this presentation. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties.

You should not place undue reliance on the forward-looking statements. For additional information, including important risk factors, please refer to BioCryst's documents filed with the SEC and located at <u>ir.biocryst.com/financial-information/sec-filings</u>.





Corporate update

Jon Stonehouse President and Chief Executive Officer

Dr. Ryan Arnold Chief Medical Officer

Charlie Gayer Chief Commercial Officer

Financial update

ORLADEYO[®] update

Anthony Doyle Chief Financial Officer



Q&A

Patients experience excellent HAE control on ORLADEYO

LONG-TERM CLINICAL EVIDENCE

Attack reduction vs baseline after 96 weeks on berotralstat 150mg in APeX-2 study

90.8%

Source: Kiani-Alikhan S, Gower R, Craig T et al. Once-daily oral berotralstat for long-term prophylaxis of hereditary angioedema: The open-label extension of the APeX-2 randomized trial. J Allergy Clin Immunol December 2023 Rapid

Rapid attack control regardless of baseline rate or C1-INH level and function

Sustained monthly attack rates after switching to ORLADEYO from other prophylaxis therapies

Sustained 🖤

Sustained attack control regardless of baseline rate or CI-INH level and function

Median monthly attack rate on ORLADEYO for patients who were attack free at baseline

Zero


Source: AAAAI Annual Meeting 2024 Poster Presentations February 2024



LONG-TERM REAL-WORLD EVIDENCE

ORLADEYO reduced attacks by 90.8% compared to baseline after 96 weeks

- Final published analysis of 96week data from the APeX-2 trial showed patients who received berotralstat 150 mg from Day 1 experienced an average reduction in monthly attack rate of 90.8% compared to baseline.
- Median attack rate at Month 24 was zero.



Source: Kiani-Alikhan S, Gower R, Craig T *et al.* Once-daily oral berotralstat for long-term prophylaxis of hereditary angioedema: The open-label extension of the APeX-2 randomized trial. *J Allergy Clin Immunol Pract* 2023; Epub ahead of print (DOI: 10.1016/j.jaip.2023.12.019)

Baseline adjusted patient-reported HAE attack rates are based on the number of HAE attacks experienced between screening and the start of Part 1 (i.e., the run-in period). BL, baseline; HAE, hereditary angioedema; SEM, standard error of the mean.




Reduced attack rates, regardless of baseline attacks

- Patients experienced rapid, substantial and sustained reductions in attacks after starting ORLADEYO, regardless of baseline attack rate
- Patients with zero attacks at baseline maintained attack control on ORLADEYO

Poster Real-world outcomes		
012 Mark Davis-Lorton ¹ , Donald S. Levy ² , Douglas T. Johnston ³ , Meri Li	/ecchi ^a , Lindsey Noble ^a , Stephanie Wasilewski ⁴ , Tyler Nadig ^a ^a , William Lumry ⁴	
"ENT and Allergy Associates, LLP, Tarrytown, MY, USA; "Division of Allergy and Immuno	ogy, University of California, Irvine, CA, USA; HisoDsyst Pharmaceuticals, Inc., Durham, NC, USA; "Optime Care, Earth City, MO, L	USA; iBeghou Consulting, Chicago, IL, USA; fAllergy & Asthma Specialists of Dallas, Dallas, TX, USA. *Former employee
RODUCTION	RESULTS	RESULTS (cont.)
fereditary angioedema (HAE) with C1-inhibitor (C1-INH) deficiency (HAE-C1-INH) is a rare inherited	 Baseline characteristics are presented in Table 1 	 In patients receiving berotralstat 110 or 150 mg QD, median monthly attack rates were reduced and
lisease characterized by unpredictable, potentially life-threatening recurrent swelling attacks most	Table 1. Summary of baseline characteristics	remained below baseline for up to 540 days regardless of their baseline values (Figure 3)
commonly affecting the extremities, face, abdomen, and larynx ^{1,2}	Characteristic Patients receiving berotrainted 110 or 150 mg QD	Figure 3. Attack rate progression according to baseline
 In HAE-C1-INH, mutations in the SERPINGI gene lead to deficient or dysfunctional C1-INH 	(N+335) Age, years, median (range) 40 (12-52)	A 90 day 31 23
protein ²	Sex, n (N)	havefine of 2 % 1.5
lerotralstat is a first-line, once-daily (QD) oral plasma kallikrein inhibitor approved for the prevention	Male 97 (29.0)	D 1 1
of HAE attacks in patients ≥12 years of age ³	Female 238 (71.0)	R 0 0.00 0.00 0.00 0.00 0.00 0.00
n the pivotal APeX-2 trial, treatment with berotralstat 150 mg QD significantly reduced HAE attack	Weight, Bo, median (range) 185 (94-405)	5 Baueline 1-90 Days 95-380 Days 181-270 Days 272-580 Days 181-450 Days 455-540 Days 1
ates compared to placebo and showed sustained effectiveness across all timepoints up to 96 weeks ^{4,5}	Prior prophylactic treatment for HAD', n (%) Yes 104 (54.3)	22 ² , 52 ⁴ percentle 0.00, 0.01 0.00, 0.33 0.00, 0.25 0.00, 0.50 0.00, 0.50 0.00, 0.57 0.00, 0.45
ere we present real-world effectiveness outcomes for patients with HAE-C1-INH in the United States	No 151 (45.3)	1.1
who initiated treatment with berotralstat	90-day patient-reported baseline attack rate ¹ , n (%)	1.90 day 11 1
THODS	0 attacks 52 (15.5) 1 to 1 attacks 109 (12.5)	baseline of 13
Data were collected through the sole-source pharmacy and included patients (N=335) who actively	4 to 9 attacks 89 (26.6)	1103 12 1 647 648 648 648 648 649
eceived berotralstat 110 or 150 mg from 12/16/2020 to 6/15/2023 and reported a 90-day baseline	200 ettecks 85 (25.4)	1 1 1 100 0
ittack rate (Figure 1)	Latest berotralstat dose, n (%) 120 mar 26 (7.8)	a 100 101 81 84 10
 Eligible patients had an international Classification of Diseases, Tenth Revision (ICD-10) code of 	150 mg 109 (92.2)	21 ⁶ , 11 ⁶ percentile 0.01, 1.00 0.00, 0.07 0.00, 0.07 0.00, 0.01 0.00
DB4.1 or T78.3 and documented plasma C1-INH level and function, as well as complement 4 (C4) level	Patients who received another prophylactic treatment for HAE at any time, including lanacidumak, IVCI-MH, SC CI-RH, danaxii, stanceolot, and oxandrolane. Presents who reported 11th attacks in the PE data prior to becomplete antitation rate out have associated a belie somether.	C.Weday 11 23 180
 Patients were classified as HAE-C1-INH if their C1-INH level and/or function, as well as C4 level. 	E3 (NY, E3 additor) NM, heroditary argunderica, 10, intraminus, 10, indextaneous.	baseline of
were below the limits of the laboratory's normal reference range	Safety	410.9 0.71 1.00 0.67 0.67 0.50 0.75
pure 1. Study design Berotraistat 110 or 150 mg QD	 Adverse events were reported in 161/335 (48%) patients 	
	Effectiveness	Beaufine 1-00 Days \$1-180 Days 181-270 Days 272-380 Days 352-450 Days 452-340 Days
laty utwo	· Overall, median HAE attack rates decreased below baseline in the first 90 days of berotralstat	295,755 persentile 1.81,2.67 0.31,1.30 0.33,1.17 0.27,1.46 0.30,2.00 0.00,1.00 0.00,1.00
lighter patients had an ICD 10 code of EMA 1 90-697 peters 5-60 96-430 161-270 271-340 961-450 651-540 prillets patients data data data data data data data da	treatment and remained below baseline across all time intervals for up to 540 days (Figure 2)	
ad fanction, as well as (4 invel) reported tanting tanti add authors received hereitabled tanting	· Similar results were observed for those patients who continued on treatment for 360 or 540 days	0.90 dw 12.3
	Figure 2. Overall attack rate progression	D. 90 day 0 2 - 1.59 L38 L42 L50 L50
De ar 15% ing (20 Hum 12/12/2009) Victorial reported a 90 day levelses fluck role Datcomes: Modian parteent-reported attacks/march/for each Datcomes: Modian parteent-reported attacks/march/for each	1	210
elisate adva regional vill attacke india 10 days prior to benetalitati to bation may not have provided a finite regional.		
-Nov, C5 whilehov, C4, complement 4, CD, vidernational OpcoRisation of Occasion, OD, once-dally.		Basedine 1-00 Days 93-180 Days 181-270 Days 271-380 Days 181-540 Days n 85 79 144 M 181 281 Days 271-380 Days 181-540 Days 281 281 281 281 281 281 281 281 281 281
Attack-rate progression: Patient-reported attack rates were collected at baseline and each refill		20 ² , 72 ³ , personille v3.33, +3.33 8.56, 540 8.58, 500 8.33, 5.00 8.33, 5.00 8.33, 5.00 8.35, 2.50 8.56, 5.13 8.26, 4.00 Ver automic with housing a straight rate of serve along a straightful to instrume.
 Baseline attack rates: Median of patients' baseline 30-day average attack rates are reported 		*Matteries advancement is the attacks in the VE days prior to benchabilitation may not have provided a finite number. ED, once data.
 The baseline 30-day average was calculated based on each patient's self-reported attack rate 	9 0 Rawline 3-00.0wv 95-380.0wv 381-270.0wv 271-380.0wv 381-490.0wv 451-040.0wv	CONCLUSIONS
for the 90 days prior to berotralstat initiation and by dividing that value by 3	8 181 181 241 188 180 141 138	Long-term prophylaxis with berotraistat in the real-world setting resulted in rapid reductions in patient-
Outcomes: Median patient-reported attack rates per month are reported for each 90-day period*	33 ¹⁰ , 79 ¹⁰ percentile 0.33, 1.33 0.46, 1.50 0.06, 1.33 0.46, 1.35 0.46, 1.25 0.06, 1.50 0.00, 1.44	Using the second section of the secti
o During each 90-day period, patients reported their attack rates at each refill (approximately every	Advanded generit. The shorty was sponsored by this Gryat Phermanetericals, Inc. Ourham, MC, USA. Metical writing and editorial assistance were provided by Porterhesset Medical and were fooded	Patients who reported a 90-day baseline attack rate of 0 maintained a low attack rate on berotralstat
30 days) and monthly attack rates were calculated by taking the average of the reported attacks	ha Bio(yy) Hannaxouticali, Inc. Rahowneas	treatment
across each 90-day period	 Parkas N. Aspert Opin Ther Targets 2010, 21 (k): 412–434. J. Ultari A. et al. Molingies 2013; 7: 103–113. S. BoCryst Pharmanechicals Sci. (PLADVO [Intercolutation capitales, for and can - prescribing federation; Nonentine 2023. 6: Jurget Rated. J. Always: Clin Intercolut. 2023; 108–117. 348-117. 348. 1. Eland Lot and Oral presentation at 	On the set of the s

Source: Berotralstat prophylaxis reduces HAE attack rates regardless of baseline attacks: Real-world outcomes Presented at the AAAAI Congress 2024 · February 23–26, 2024




MEDIAN MONTHLY ATTACK RATE PROGRESSION BY BASELINE RATE


bio cryst | 6


Sustained attack control, regardless of prior prophy

 Patients experienced sustained median attack rates of approximately 0.5 per month on ORLADEYO, regardless of prior prophylaxis therapy



MEDIAN MONTHLY ATTACK RATE BY PRIOR PROPHYLAXIS








Reduced attack rates, regardless of C1-INH level and function

 Patients who initiated ORLADEYO experienced rapid, substantial and sustained reductions in attack rates through 18 months of treatment regardless of their C1-inhibitor (C1-INH) level and function



<text><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item> () ()) ()) ()) ()) ()) ()) ()) ())</list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></text>	281 James Tracy ¹ , John Anderson ¹ , Douglas T. Johnston ¹ , Meri Li					25t
<text><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></text>		Vecchi ¹ , Lindsey Noble ¹ , Stephanie Wasilewski ⁴ , Tyler	r Nadig ^{s*} , Daniel Soteres*			75t
<text><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></text>	Werge Anthrea & Immunology Associates, PC., Omaha, NE, USA; Wervile Health	h, Birmingham, AL, USA; 'BioCryst Pharmaceuticali, Inc., Durham, NC, U	15A; *Optime Care, Earth City, MO,	USA, 'Beghou Consulting, Osicag	p, K, USA, Hathma & Allergy Associates, P.C., Colorado Springs, CO, USA. *Former employee	
<text><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></text>	ITRODUCTION	METHODS (cont.)			RESULTS (cont.)	Perce
<text><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></text>	Hereditary angioedema (HAE) is a rare inherited disease characterized by unpredictable, recurrent	 Attack-rate progression: Patient-reported attack 	rates were collected at basel	ine and each refill	and a second sec	
<text><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></text>	episodes of bradykinin-mediated angioedema most commonly affecting the extremities, face,	 Baseline 30-day average was calculated based on 	each patient's self-reported	attack rate for the 90		
<list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item>	abdomen, and larynx ^{L1}			PORCE FROM FOR ONE PO		
<text><text><text><text><text><text><text><text><text><text><text><text><text></text></text></text></text></text></text></text></text></text></text></text></text></text>	o In HAE with C1-inhibitor deficiency (HAE-C1-INH), mutations in the SERPING1 gene lead to			sk oter an mosted	patients with HAE-ni-C1-INH	
<text><text><text><text><text><text><text><text><list-item><list-item><list-item><list-item><list-item></list-item></list-item></list-item></list-item></list-item></text></text></text></text></text></text></text></text>			Outcomes: Median patient-reported attack rates per month are reported for each 90-day period		Effectiveness	
<text><text><text><text><text><text><text><text><list-item><list-item><list-item><list-item><list-item><list-item></list-item></list-item></list-item></list-item></list-item></list-item></text></text></text></text></text></text></text></text>						
<text><text><text><text><text><text><list-item><list-item><list-item><list-item><list-item><list-item></list-item></list-item></list-item></list-item></list-item></list-item></text></text></text></text></text></text>						_
<text><text><text><text><text><text><text><text></text></text></text></text></text></text></text></text>			interval (approximately 30 d	ays) ronowing their first		
<text><text><text><text><text><list-item><list-item><list-item><list-item><list-item></list-item></list-item></list-item></list-item></list-item></text></text></text></text></text>	of HAE attacks in patients 212 years of age ³	Patients who reported +10 attacks in the 30 days prior to benchulated initials	on may not have provided a firster number.	Wart all patients reported a		
<text><text><text><text><list-item><list-item><list-item><list-item><list-item></list-item></list-item></list-item></list-item></list-item></text></text></text></text>			e period.			
<text><text><list-item><list-item><list-item>mich with the situate structure to the si</list-item></list-item></list-item></text></text>					A Protect and Add Coloma	
The design de						
$\frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ $	sericiency who initiated berotraistat in the United states		r patients with HAE-C1-INH i	ind HAE-rel-C1-INH are	2-1 E1	
har sure discled forces planetary planetary and its dudies planetary shares and planetary and its dudies planetary and it	THODS					
$\frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ $		Table 1. Summary of baseline characteristics	And on the	Budium and	11 11 11 11	
$\frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ $		Ownerstandste				
 Provide started start s						
$ \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \\ \\ \end{array} $		Age, years, median (range)				
 The Tot indication of the strate of the strat		Sex, n (%)			Andre 140 10.00 10.00 10.00 00.00 00.00 Rod	
$ \begin{array}{c} 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 $		Male	120 (29.9)	75 (24.8)		
set black da hund, of the laboratory's small inference radio Weight, Small Small, Call, Small, Sma		Female	282 (70.1)	227 (75.2)	No. 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.	
a · A definition werd durch de Auk (-4 - 2, bit of the patient's) aligned - 2, bit of the patient's planes - 2, bit of the patient'			169 (94-405)		Prostite 100/71-001 benefities antisofares with /71-000bites deficience 100 a/71-001 benefities antisofares with second /71-000bites	
We define the binds of the biodstopy's more than the biodstopy's mo						
ex 1. Should have been approximately a should be should be a should be a should be should be a should be a should		Prior androgen user	66 (16.4)	24 (4.6)	CONCLUSIONS	
Annual Control Annual control (no do not (no do						
And all a log all all all all all all all all all al	re 1. Study design	Prior SC C3-INH use	77 (19.2)	46 (15.2)		
Name Market Market Back Description Des	Berstrakter 110 og 00	Prior lanadelumab-use	99 (24.6)	85 (28.1)	C1-INH deficiency	
And an additional additionadditionadditional additional additional additional additional addi	Righting strate				Monthly attack rates remained consistently below baseline in patients with and without C1-INH	
at table at table at table bit at table<						
Processed of a finite of the control of the contr	Articularitation and price departs in the last state and the				Instruktet war energie well telepted	
And the second s	Television State (State				•	
Non-sequence Description Description <thdescription< th=""> <thdescription< th=""></thdescription<></thdescription<>	Benarissia Cales					
The second secon	Actively method for shellow Actively methods and a standard structure of the south the		85 (25.4)	122 (49.0)	 option for long-term prophylaxis of HAE 	
The second secon	KUNA/WERE IN ACTIVITIES BUT ACTIVITIES BUT ACTIVITIES AND ACTIVITIES A		10.00.00	P.C. (21.4 PD		
Values and second secon						
					and anny handled by BioCypt Pharmaceuticals, Inc.	
acroso G 481 (G). Iterative of Desaus, QJ, sec 6dy.	LE VIN, CE UMBRED, CR, LENGREDER K, MILL CE MAY, NEURINELY angleschera and CE MAY detecting, MAL 2015, MAY, NEURINELY angleschera and normal CE 4001, KE, International Case/Faction of Diseases, QD, ance daily.	benateriumah are net mahasha melanise. Prelades darand, stanamisi, and osa	estrations.		Menon .	

MONTHLY ATTACK RATE BY C1-INH DEFICIENCY





Source: Real-world effectiveness of berotralstat in HAE with and without C1-inhibitor deficiency Presented at the AAAAI Congress 2024 · February 23–26, 2024

Historically, patients on injectable prophylaxis report low but consistent attack rates

 Patients taking injectable prophylaxis therapies have reported mean attack rates in the range of 0.3 to 0.6 per month

MEAN # OF ATTACKS IN PAST 3 MONTHS (2018-2019 PATIENT SURVEY DATA)





Source: Hereditary Angioedema Patients in the United States Report Expanded Use of Prophylaxis, but Continue to Experience Attacks *Presented at the EAACI Digital Congress 2020 · June 6-8, 2020*



Approved label: ORLADEYO (berotralstat) safety

In APeX-2 (part 1), the most common treatment-emergent adverse reactions^a were abdominal pain, vomiting, diarrhea, back pain, and gastroesophageal reflux disease (GERD)

Adverse reactions	Placebo (n=39)	ORLADEYO 110 mg (n=41)	ORLADEYO 150 mg (n=40)
Adverse reactions	n (%)	n (%)	n (%)
Abdominal pain ^b	4 (10)	4 (10)	9 (23)
Vomiting	1 (3)	4 (10)	6 (15)
Diarrhea ^c	0	4 (10)	6 (15)
Back pain	1 (3)	1 (2)	4 (10)
GERD	0	4 (10)	2 (5)

Findings from the open-label, long-term safety study, APeX-S (interim safety population, n=227), support the data observed in APeX-2 (part 1)


 a ≥10% and higher than placebo.

^b Includes abdominal pain, abdominal discomfort, abdominal tenderness, and upper abdominal pain.

^c Includes diarrhea and frequent bowel movements.




MARKET RESEARCH: Intent to prescribe more ORLADEYO remains consistent, with prescriptions coming mostly from prophylactic switches



SOURCE OF FUTURE NEW ORLADEYO PRESCRIPTIONS - 2024

(n=154 unique A/Is managing ~1,300 HAE patients)




A/Is expect future new ORLADEYO prescriptions to come ~2/3 from prophylaxis switches and ~1/3 from On-Demand Only

Future **ORLADEYO** prescribing has been <u>consistent throughout all of 2022-23</u>

Source: BioCryst Internal Market Research Studies (Conducted Feb 2023, May 2023, Sep 2023, and Dec 2023)



Path to \$800M US revenue in 2029



ASSUMPTIONS

- 15-20% gross-to-net on Paid shipments
- Compliance in low-90s%

* PAP is the company's long-term patient assistance program



Finance summary

(FIGURES IN MILLIONS)

Q4 2023 CASH POSITION	
Cash, cash equivalents, restricted cash & investments at December 31, 2022	\$444
Cash, cash equivalents, restricted cash & investments at December 31, 2023	\$391
Senior credit facility ^A	\$314

2024 FY GUIDANCE	
ORLADEYO revenue	\$380-400
Operating expenses (excluding non-cash comp)	\$365-375

A – From Pharmakon Advisors, \$300M drawn at issuance in Q2 2023. The \$314M balance above represents \$300M initial issuance plus PIK interest to-date (eligible to PIK 50% per quarter for first six quarters).



Fourth Quarter and Full Year 2023 Results Call

Corporate Update & Financial Results February 26, 2024



